Darovasertib plus Crizotinib for Metastatic Uveal Melanoma
KIMMTRAK, the only FDA-approved systemic treatment for metastatic uveal melanoma, can be used only by patients with a tissue type called HLA-A*02:01. An estimated 50% to 70% of patients do not have this tissue type.
The phase 2/3 OptimUM-02 trial studied two oral drugs, darovasertib and crizotinib, in 313 patients with metastatic uveal melanoma who did not have HLA-A*02:01 and had not received prior treatment for metastatic disease. Results presented in 2026 compared the combination with the immunotherapy patients would otherwise typically receive:
The phase 2/3 OptimUM-02 trial studied two oral drugs, darovasertib and crizotinib, in 313 patients with metastatic uveal melanoma who did not have HLA-A*02:01 and had not received prior treatment for metastatic disease. Results presented in 2026 compared the combination with the immunotherapy patients would otherwise typically receive:
- Tumors shrank in 37% of patients on the combination and 6% on immunotherapy.
- Median time before the cancer grew was 6.9 months on the combination and 3.1 months on immunotherapy.
Pills Before Eye Treatment to Shrink the Tumor (OptimUM-10)
A phase 3 clinical trial is enrolling adults who have just been diagnosed with uveal melanoma and have not yet been treated. It is testing whether taking darovasertib, a pill that targets the main driver of uveal melanoma, before standard treatment can shrink the tumor and help save the eye and vision.
Participants are randomly assigned either to take darovasertib first and then receive standard treatment (plaque radiation, proton radiation or surgery), or to go straight to standard treatment. In an earlier study, most patients’ tumors shrank on darovasertib.
The trial aims to enroll about 520 patients at roughly 90 sites. If you have just been diagnosed, ask your ocular oncologist whether you might qualify, or search NCT07015190 on ClinicalTrials.gov. Questions? Email info@ocularmelanoma.org.
Participants are randomly assigned either to take darovasertib first and then receive standard treatment (plaque radiation, proton radiation or surgery), or to go straight to standard treatment. In an earlier study, most patients’ tumors shrank on darovasertib.
The trial aims to enroll about 520 patients at roughly 90 sites. If you have just been diagnosed, ask your ocular oncologist whether you might qualify, or search NCT07015190 on ClinicalTrials.gov. Questions? Email info@ocularmelanoma.org.




